Dr. Han Ying has been the Chief Executive Officer and a Board member at Gyre Therapeutics since January 2024. Dr. Ying was previously a director at Gene Corporation and Base Therapeutics, which he co-founded in 2021. His entrepreneurial achievements include co-founding Immunnova, leading acquisitions of Dendreon and China Life Science, and joined founding team of T-Cure Bioscience. He has also served as Chief Scientific Officer at Immunotech Biopharm Ltd., and held scientific positions at Berlex Biosciences and Monogram Biosciences. Additionally, Dr. Ying is a venture partner at Panacea Venture. He is renowned for his scientific contributions, with multiple papers in Nature Medicine, particularly for pioneering work in RNA and DNA vaccine development. Dr. Ying earned his Ph.D. in Cancer Biology from Stanford University and completed his postdoctoral training under Drs. Steven Rosenberg and Nicholas Restifo at the National Cancer Institute.